AstraZeneca announced in May 2026 that its drug Ultomiris significantly reduced urine protein levels in patients with IgA ...

New research shows European and UK B2B payment leaders are prioritizing AI adoption, flexible payment terms, and regional customization to meet rising buyer expectations amid economic and regulatory ...

A new analysis by researchers at The University of Texas MD Anderson Cancer Center demonstrates that a combination therapy ...

B cells are white blood cells that form a core part of the body's adaptive immune system, enabling it to recognize specific ...

IgA nephropathy (IgAN) is a kidney condition where antibodies (immune system proteins) build up and cause damage in your kidneys. IgAN, also known as Berger's disease, does not have a cure. However, ...

Many novel treatment approaches are being investigated to halt progression of geographic atrophy (GA) or, potentially, even reverse the retinal damage. The major categories include novel complement ...

Complement 3 glomerulopathy (C3G) is a rare kidney disease caused by problems in the body's complement system, which normally helps fight infections. It damages tiny filters in your kidneys called ...

Novartis’ kidney disease troika keeps marching forward. With a new FDA approval, the company’s Fabhalta has become the first treatment endorsed by the agency for the ultrarare kidney disease ...

Fabhalta® is the first oral monotherapy for previously treated and treatment-naïve adults with paroxysmal nocturnal hemoglobinuria (PNH) 1,2 Significant unmet need remains in PNH, a chronic, rare and ...